Business Wire

SYMPA

25.8.2020 09:02:06 CEST | Business Wire | Pressemeddelelse

Del
HR-teknologiselskabet Sympa accelererer og satser på global vækst sammen med en ny ejer

HR-teknologiselskabet Sympa offentliggjorde i dag, at de har godkendt en majoritetsinvestering fra Providence Strategic Growth (“PSG”). PSG er et datterselskab af Providence Equity Partners, en af ​​verdens førende kapitalfonde med fokus på teknologiselskaber. Det nordiske investeringsselskab Alfvén & Didrikson, der investerede i Sympa i 2016, forbliver minoritetsejere sammen med Sympas stiftere. Edward Hughes, Aldo Mareuse og Tobias Richter fra PSG sidder nu i Sympas bestyrelse. Ingen finansielle detaljer er offentliggjorte.

Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200825005033/da/

“Vi valgte Sympa som partner, fordi det er et veldrevet og spændende firma med stort potentiale, som er på forkant med udviklingen af ​​europæiske HR-systemer” siger Edward Hughes, CEO hos PSG. “Markedet vokser hurtigt, og virksomheder efterspørger nu avancerede digitale HR-værktøjer, hvilket skaber interessante vækstmuligheder for Sympa. Vi ser frem til at samarbejde med Keijo og hans team for at nå virksomhedens fulde potentiale og fremskynde den internationale ekspansion.”

Sympa blev grundlagt i 2005 og er i dag en af Nordens førende og hurtigst voksende leverandører af cloud-baserede HR-løsninger. Selskabets mest populære produkt, Sympa HR, er en omfattende HR-løsning for digital håndtering af HR, som giver et tydeligt overblik over medarbejderdata og HR-processer. PSG’s investering vil understøtte Sympas næste vækstfase; produktudvikling og strategisk M&A for at fremme ekspansionen i hele Europe. Medstifter og CEO Keijo Karjalainen fortsætter med at stå i spidsen for både den daglige drift og Sympas team bestående af 140 medarbejdere, fordelt på 8 kontorer i 5 lande.

“Lige siden vi grundlagde Sympa, har vi været overbevist om, at der er et uudforsket behov for HR-systemer, der kan håndtere alle HR-processer og muliggøre datadrevet HR-arbejde. Vi har også identificeret en mangel på HR-systemer til mellemstore virksomheder med aktiviteter i flere forskellige lande og den kompleksitet, det medfører. Ved at imødekomme begge disse behov og samtidig sætte kunden først, har Sympa været i stand til at vokse hurtigt, og med PSG på vores side, mener vi, at der er meget gode vilkår for at få en markedsledende position uden for vores nordiske hjemmemarkeder. Det bliver meget spændende at se, hvad fremtiden har at vise” siger Keijo Karjalainen, medstifter og CEO.

Sympa hjælper i øjeblikket mere end 700 virksomheder verden over med at fremme udviklingen af deres medarbejdere, strømline HR-processerne og træffe endnu smartere strategiske beslutninger. Sympas kunder inkluderer flere kendte brands som Dustin, LandboNord, WhiteAway, VMS Group og Napatech. Sympa har tidligere toppet IT-magasinet Red Heerings liste med de 100 mest lovende start-ups.

Om Sympa

Sympa HR er en komplet HR-løsning, der nemt kan tilpasses, så den matcher virksomheden perfekt, og brugerne kan fokuserer på medarbejderne og smart beslutningstagning. HR-løsningen giver et tydeligt og samlet overblik over alle medarbejderdata, hjælper med at automatisere en lang række af de daglige HR-opgaver og samler alle HR-data et sikkert sted. Sympa HR anvendes nu gennemsnitligt 650.000 gange hver måned i 700+ virksomheder i mere end 100 lande. I 2019 vandt Sympa ”Året HR-systemprojekt ”, og har en de højeste kundetilfredshedsrater inden for HR-teknologi i Europa. Læs mere om Sympa HR-løsningen og selskabet kunder på sympa.dk .

Om Providence Strategic Growth

PSG, et datterselskab af Providence Equity Partners (“Providence”), blev etableret i 2014 og fokuserer på kapitalinvesteringer i teknologiselskaber med stærk vækst. Providence er et førende kapitalforvaltningsselskab, der har en sektorfokuseret investeringsstrategi. Siden selskabets start i 1989 har Providence investeret i mere end 200 virksomheder og er en af de førende kapitalfonde med fokus på medier, kommunikation, uddannelse, software og serviceindustrien. Providence har tidligere investeret i TDC. Selskabet har hovedsæde i Boston, USA, og kontorer i London og Kansas City. Læs mere på https://www.provequity.com .

Om Alfvén & Didrikson

Det svenske investeringsselskab Alfvén & Didrikson er et veletableret selskab, som specialiserer sig i passionerede start-ups med internationale vækstambitioner. Siden 2010 har Alfvén & Didrikson investeret i hurtigt voksende nordeuropæiske virksomheder, som eksempelvis Quinyx, Trustly, Mentimeter, Acast, Offerta og PE Accounting. Læs mere på www.alfvendidrikson.com .

Link:

ClickThru

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Følg pressemeddelelser fra Business Wire

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra Business Wire

Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release

Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP

Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release

Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp

KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release

Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen

Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR

Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli

I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.

Besøg vores nyhedsrum
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye